ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension - 
69310001 GlaxoSmithKline AG
AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension02.05.2024
  02.05.2024
  
 01.05.2029
 
08.08. 
B  
No 
IP 
PR  
k.A.PR
  
7680693100015Impfstoffe
  
Composition
I): proteinum prae-fusionatum F viri sincitialis respiratorii 120 µg, trehalosum dihydricum, polysorbatum 80, kalii dihydrogenophosphas, dikalii phosphas anhydricus, pro vitro. II): Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. I) et II) corresp.: proteinum prae-fusionatum F viri sincitialis respiratorii 120 µg, trehalosum dihydricum, polysorbatum 80, kalii dihydrogenophosphas, dikalii phosphas anhydricus, Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, natrii chloridum, dinatrii phosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.78 mg, kalium 0.35 mg.
Packungsbestandteile
 
Source
Data was imported : 07.06.2024 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home